Education
About Us
Working with TipRanks
Follow Us
Eterna Therapeutics (ERNA)
NASDAQ:ERNA
Total Valuation
Eterna Therapeutics has a market cap or net worth of $16.27M. The enterprise value is $15.39M.
Market Cap$16.27M
Enterprise Value$15.39M
Share Statistics
Eterna Therapeutics has 7,361,201 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding7,361,201
Owned by Insiders32.72%
Owned by Institutions0.76%
Financial Efficiency
Eterna Therapeutics’s return on equity (ROE) is -26.18 and return on invested capital (ROIC) is -617.99%.
Return on Equity (ROE)-26.18
Return on Assets (ROA)-8.45
Return on Invested Capital (ROIC)-617.99%
Return on Capital Employed (ROCE)-6.72
Revenue Per Employee97.00K
Profits Per Employee-7.42M
Employee Count6
Asset Turnover0.11
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of {name} is {pe}. {name}’s PEG ratio is {priceToEarningsGrowthRatio}.
PE Ratio―
PS Ratio0.00
PB Ratio-17.58
Price to Fair Value2.36
Price to FCF-1.00
Price to Operating Cash Flow-7.39
PEG Ratio-0.16
Income Statement
In the last 12 months, Eterna Therapeutics had revenue of 582.00K and earned -44.54M in profits. Earnings per share was -1.57.
Revenue582.00K
Gross Profit486.00K
Operating Income-15.67M
Pretax Income-44.51M
Net Income-44.54M
EBITDA-36.12M
Earnings Per Share (EPS)-1.57
Cash Flow
In the last 12 months, operating cash flow was -14.15M and capital expenditures -268.00K, giving a free cash flow of -14.42M billion.
Operating Cash Flow-14.15M
Free Cash Flow-14.42M
Free Cash Flow per Share-1.96
Dividends & Yields
Eterna Therapeutics pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta1.12
52-Week Price Change-92.27%
50-Day Moving Average2.53
200-Day Moving Average5.79
Relative Strength Index (RSI)48.04
Average Volume (3m)98.25K
Important Dates
Eterna Therapeutics upcoming earnings date is ―, ―.
Last Earnings Date―
Next Earnings Date―
Ex-Dividend Date―
Financial Position
Eterna Therapeutics as a current ratio of 0.80, with Debt / Equity ratio of -48.44%
Current Ratio0.80
Quick Ratio0.80
Debt to Market Cap0.05
Net Debt to EBITDA0.03
Interest Coverage Ratio-2.32
Taxes
In the past 12 months, Eterna Therapeutics has paid 30.00K in taxes.
Income Tax30.00K
Effective Tax Rate>-0.01
Enterprise Valuation
Eterna Therapeutics EV to EBITDA ratio is -0.08, with an EV/FCF ratio of -0.18.
EV to Sales5.10
EV to EBITDA-0.08
EV to Free Cash Flow-0.18
EV to Operating Cash Flow-0.19
Balance Sheet
Eterna Therapeutics has $1.92M in cash and marketable securities with $2.88M in debt, giving a net cash position of $964.00K billion.
Cash & Marketable Securities$1.92M
Total Debt$2.88M
Net Cash$964.00K
Net Cash Per Share$0.13
Tangible Book Value Per Share-$0.03
Margins
Gross margin is 80.75%, with operating margin of -2693.13%, and net profit margin of -7652.75%.
Gross Margin80.75%
Operating Margin-2693.13%
Pretax Margin-7647.59%
Net Profit Margin-7652.75%
EBITDA Margin-6206.01%
EBIT Margin-6487.46%
Analyst Forecast
The average price target for Eterna Therapeutics is ―, which is 11.43% higher than the current price. The consensus rating is ―
Price Target―
Price Target Upside―
Analyst Consensus―
Analyst Count0
Revenue Growth Forecast―
EPS Growth Forecast―